PTCT
Price
$45.88
Change
-$0.33 (-0.71%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
3.61B
69 days until earnings call
RARE
Price
$35.66
Change
+$0.15 (+0.42%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
3.36B
69 days until earnings call
Interact to see
Advertisement

PTCT vs RARE

Header iconPTCT vs RARE Comparison
Open Charts PTCT vs RAREBanner chart's image
PTC Therapeutics
Price$45.88
Change-$0.33 (-0.71%)
Volume$17.44K
Capitalization3.61B
Ultragenyx Pharmaceutical
Price$35.66
Change+$0.15 (+0.42%)
Volume$16.91K
Capitalization3.36B
PTCT vs RARE Comparison Chart
Loading...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTCT vs. RARE commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTCT is a Buy and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (PTCT: $46.21 vs. RARE: $35.51)
Brand notoriety: PTCT and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTCT: 2% vs. RARE: 56%
Market capitalization -- PTCT: $3.61B vs. RARE: $3.36B
PTCT [@Biotechnology] is valued at $3.61B. RARE’s [@Biotechnology] market capitalization is $3.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTCT’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • PTCT’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, PTCT is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTCT’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • PTCT’s TA Score: 5 bullish, 3 bearish.
  • RARE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PTCT is a better buy in the short-term than RARE.

Price Growth

PTCT (@Biotechnology) experienced а +1.99% price change this week, while RARE (@Biotechnology) price change was +1.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

PTCT is expected to report earnings on Jul 31, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTCT($3.61B) has a higher market cap than RARE($3.36B). PTCT YTD gains are higher at: 2.370 vs. RARE (-15.593). PTCT has higher annual earnings (EBITDA): 839M vs. RARE (-449.9M). PTCT has more cash in the bank: 2.03B vs. RARE (494M). RARE has less debt than PTCT: RARE (38.3M) vs PTCT (390M). PTCT has higher revenues than RARE: PTCT (1.77B) vs RARE (591M).
PTCTRAREPTCT / RARE
Capitalization3.61B3.36B107%
EBITDA839M-449.9M-186%
Gain YTD2.370-15.593-15%
P/E Ratio6.99N/A-
Revenue1.77B591M300%
Total Cash2.03B494M410%
Total Debt390M38.3M1,018%
FUNDAMENTALS RATINGS
PTCT vs RARE: Fundamental Ratings
PTCT
RARE
OUTLOOK RATING
1..100
1212
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5663
P/E GROWTH RATING
1..100
23100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (79) in the Biotechnology industry is in the same range as PTCT (99). This means that RARE’s stock grew similarly to PTCT’s over the last 12 months.

RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PTCT (100). This means that RARE’s stock grew similarly to PTCT’s over the last 12 months.

RARE's SMR Rating (98) in the Biotechnology industry is in the same range as PTCT (100). This means that RARE’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's Price Growth Rating (56) in the Biotechnology industry is in the same range as RARE (63). This means that PTCT’s stock grew similarly to RARE’s over the last 12 months.

PTCT's P/E Growth Rating (23) in the Biotechnology industry is significantly better than the same rating for RARE (100). This means that PTCT’s stock grew significantly faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTCTRARE
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
72%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QSMRX18.270.02
+0.11%
AQR Small Cap Momentum Style R6
AFMBX34.910.03
+0.09%
American Funds American Balanced F3
GGHCX35.28N/A
N/A
Invesco Health Care A
MSEQX60.02N/A
N/A
Morgan Stanley Inst Growth I
GCSUX25.81N/A
N/A
Goldman Sachs Small Cap Eq Insghts R6

PTCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTCT has been loosely correlated with ACLX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PTCT jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTCT
1D Price
Change %
PTCT100%
N/A
ACLX - PTCT
44%
Loosely correlated
-0.50%
ERAS - PTCT
43%
Loosely correlated
N/A
COGT - PTCT
43%
Loosely correlated
N/A
RXRX - PTCT
43%
Loosely correlated
N/A
XNCR - PTCT
42%
Loosely correlated
+2.26%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with CRNX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+0.28%
CRNX - RARE
52%
Loosely correlated
+0.53%
COGT - RARE
52%
Loosely correlated
N/A
RVMD - RARE
50%
Loosely correlated
+0.15%
RCKT - RARE
48%
Loosely correlated
N/A
RNA - RARE
48%
Loosely correlated
N/A
More